<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72144">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845142</url>
  </required_header>
  <id_info>
    <org_study_id>ViDImmun</org_study_id>
    <secondary_id>2012-003217-33</secondary_id>
    <nct_id>NCT01845142</nct_id>
  </id_info>
  <brief_title>Immunologic Action of a Single Dose Cholecalciferol</brief_title>
  <acronym>ViDImmun</acronym>
  <official_title>Immunologic Functions of a Single Dose of 100.000 I.U. Cholecalciferol (Vitamin D3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margitta Worm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D receptors are expressed in activated different immune cells. It is not known,
      which immune cell type is targeted by exogenous vitamin D. Here, vitamin D-deficient
      individuals will receive once 100.000 I.U. vitamin D3 either intramuscular or subcutaneous
      in a double-blind placebo controlled setting. Immune cells will be monitored from the blood
      over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D-deficient individuals will receive once

        -  double-blind, placebo controlled 100.000 I.U.vitamin D3

        -  intramuscular or subcutaneous

      Blood will be taken over time and

        -  immune cells (T cells, B cells, myeloid antigen presenting cells) are characterized by
           flow-cytometry

        -  vitamin D-metabolites will be monitored
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in the numbers of vitamin D-responsive B cells after vitamin D administration.</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peripheral B cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and characterized by flow-cytometry. Vitamin D-responsive B cells will be quantified before and 1 week, 1 month and 3 months after vitamin D administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize vitamin D-responding myeloid immune cells</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>peripheral blood mononuclear cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and monocytes will be characterized phenotypically by flow-cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of vitamin D on specific humoral memory</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The humoral immunoglobulin response against selected endogenous viruses (anti-virus-specific-Ig) over time will be determined before and 3 months after vitamin D administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D pharmacokinetics</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vitamin D-metabolites including 25-hydroxyvitamin D will be determined up to 3 months after administration of a single dose-vitamin D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize vitamin D-responsive T cells</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>peripheral T cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and characterized by flow-cytometry according to functional subpopulations.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>intramuscular 100.000 I.U. vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular 100.000 I.U. vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intramuscular placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramuscular 0.9% sodium chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous 100.000 I.U. vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous 100.000 I.U. vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single administration of 100.000 I.U. vitamin D</intervention_name>
    <arm_group_label>intramuscular 100.000 I.U. vitamin D3</arm_group_label>
    <arm_group_label>subcutaneous 100.000 I.U. vitamin D3</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>intramuscular placebo</arm_group_label>
    <arm_group_label>subcutaneous placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  18-60 yrs

          -  25-hydroxyvitamin D serum below 50 nmol/L

          -  women only: effective contraception

        Exclusion Criteria:

          -  25-hydroxyvitamin D serum above 50 nmol/L

          -  body-mass index &lt;18 or &gt;30 kg per m2

          -  planned UV-exposure (UV-index &gt; 5)

          -  hypersensitivity to vitamin D

          -  history of hypercalcemia, kidney stones, kidney insufficiency, sarcoidosis,
             pseudohyperparathyroidism concomitant vitamin A- and/or vitamin D treatment

          -  treatment with immunosuppressants, immunomodulators, phenytoin, barbiturate,
             thiazide-diuretics, glycosides

          -  immobile patients

          -  out of normal range on screening visit (calcium,phosphate,creatinin,hematology)

          -  psychiatric hospitalization

          -  pregnancy / breast-feeding

          -  dependency / relationship on sponsor

          -  concomitant participation in other clinical trials (30 days before)

          -  drug or alcohol abuse

          -  lack of compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margitta Worm, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dpt of Dermatology and Allergology, Charit√© University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Margitta Worm</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>vitamin D deficiency</keyword>
  <keyword>immune cells</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>&lt; 50 nmol/L 25(OH)D serum concentration</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
